Lecithin [phosphatidylcholine (PC)] was shown to account for more than 70% of total phospholipids within the intestinal mucus layer. It is arranged in lamellar membranes (surfactant-like particles) and establishes a hydrophobic barrier preventing invasion of the colonic commensal microbiota. In ulcerative colitis (UC), the mucus PC content was demonstrated to be reduced by about 70%, irrespective of the presence of inflammation. This may be of primary pathogenetic significance allowing bacteria to enter the mucus and induce mucosal inflammation. Therefore, a new therapeutic strategy is being developed to substitute the missing mucus PC content in UC. Indeed, a delayed-release PC formulation was able to compensate the lack of PC and improve the inflammatory activity. In randomized controlled studies, delayed-release PC was proven to be clinically and endoscopically effective, which now awaits a phase III authority approval trial.

Keywords:
Mucus, Phosphatidylcholine, Lecithin, Ulcerative colitis
1.
Shirazi T, Longman RJ, Corfield AP, Probert CSJ: Mucins and inflammatory bowel disease. Postgrad Med J 2000;76:473-478.
2.
Lamont JT: Mucus: the front line of intestinal mucosal defense. Ann NY Acad Sci 1992;664:190-201.
3.
DeSchryver-Kecskemeti K, Eliakim R, Carroll S, Stenson WF, Moxley MA, Alpers DH: Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989;84:1355-1361.
4.
Butler BD, Lichtenberger LM, Hills BA: Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983;244:G645- G651.
5.
Hicks AM, DeLong CJ, Thomas MJ, Samuel M, Cui Z: Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta 2006;1761:1022-1029.
6.
Lichtenberger LM: The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-583.
7.
Willumeit R, Schuster A, Iliev P, Linser S, Feyerabend F: Phospholipids as implant coatings. J Mater Sci Mater Med 2007;18:367-380.
8.
Guo W, Andersson R, Odselius R, Ljungh A, Wadström T, Bengmark S: Phospholipid impregnation of abdominal rubber drains: resistance to bacterial adherence but no effect on drain-induced bacterial translocation. Res Exp Med (Berl) 1993;193:285-296.
9.
Hills BA: Surface-active phospholipid: a Pandora's box of clinical applications. 2. Barrier and lubricating properties. Intern Med J 2002;32:242-251.
10.
Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W: Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-742.
11.
Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R: Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;15:1705-1720.
12.
Braun A, Schoenfeld U, Welsch T, Kadmon M, Funke B, Gotthardt D, Zahn A, Autschbach F, Kienle P, Zharnikov M, Grunze M, Stremmel W, Ehehalt R: Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis 2011;26:898-998.
13.
Hills BA: Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it. Gut 1993;34:588-593.
14.
Ehehalt R, Jochims C, Lehmann WD, Erben G, Staffer S, Reininger C, Stremmel W: Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004;1682:63-71.
15.
Alpers DH, Zhang Y, Ahnen DJ: Synthesis and parallel secretion of rat intestinal alkaline phosphatase and a surfactant-like particle protein. Am J Physiol 1995;268:E1205-E1214.
16.
Engle MJ, Grove ML, Becich MJ, Mahmood A, Alpers DH: Appearance of surfactant-like particles in apical medium of Caco-2 cells may occur via tight junctions. Am J Physiol 1995;268:C1401-C1413.
17.
Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P: Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142:473-481.
18.
Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-971.
19.
Stremmel W, Ehehalt R, Autschbach F, Karner M: Efficacy of retarded release phosphatidylcholine for treatment of chronic, steroid refractory ulcerative colitis. Ann Intern Med 2007;147:603-610.
20.
Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M: Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose-finding study. J Clin Gastroenterol 2010;44:e101-e107.
21.
Karner M, Kocjan A, Stein J, v. Boyen G, Uebel P, Schmidt C, Kupcinskas L, Dina I, Hanemann A, Zuelch F, Keilhauer G, Stremmel W: Modified release phosphatidylcholine ‘LT-02' in active ulcerative colitis: a randomized, placebo-controlled multicentre study (abstract). Gastroenterology 2012;142:suppl 1.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.